ArticleNPJ digital medicine2025
Personalised & optimised therapy (POT) algorithm using five cognitive and behavioural skills for subthreshold depression.
Article in NPJ digital medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Harnessing digital health interventions to address the heterogeneity of depression: a systematic review.Frontiers in digital health · 2025Pooled it
- Smartphone CBT engagement and depressive symptoms: secondary analysis of the RESiLIENT trial using a time-varying exposure approach.Psychological medicine · 2026Trial
- Effects of smartphone cognitive behavioural therapy on social functioning in non-depressive and subthreshold depressive adults: a secondary analysis of the RESiLIENT trial.BMJ mental health · 2026Trial
- Prediction of Treatment Benefit With Internet-Based Cognitive Behavioral Therapy for Depression.JAMA network open · 2026Article
- The Analytical Framework of Clinical Trials Evaluating Clinical Outcomes of Artificial Intelligence-Based Digital Health Interventions: A Systematic Literature Review.Journal of market access & health policy · 2026Review
- Article
- Application of artificial intelligence in schizophrenia rehabilitation management: a systematic scoping review.Translational psychiatry · 2026Article
- Safety and preliminary efficacy of Aurora: a pilot, non-randomized clinical trial of a culturally adapted digital cognitive behavioral therapy intervention for anxiety and depression in Mexico.Frontiers in psychiatry · 2026Article
- Smartphone based cognitive behavioural therapy for adults with no or minimal depressive symptoms in Japan: an exploratory secondary analysis of RESiLIENT trial.The Lancet regional health. Western Pacific · 2025Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors.
Funding
Abstract
Personalising psychotherapies for depression may enhance their efficacy. We conducted a randomised controlled trial of smartphone cognitive-behavioural therapy (CBT) among 4,469 adults in Japan (RESiLIENT trial, UMIN-CTR UMIN000047124). Participants received one of nine CBT skills or combinations, or a health information control (HI), over six weeks. All interventions were found efficacious. We developed prescriptive models using machine learning to forecast changes on the Patient Health Questionnaire-9 (PHQ-9) at week 26 and created a personalised and optimised therapy (POT) algorithm that recommended the most suitable CBT for each participant. In a simulated randomised comparison, the effect of POTs over HI was a difference by -1.41 (95%CI: -1.91 to -0.90) points on the PHQ-9 corresponding with a standardised mean difference of -0.37 (-0.49 to -0.23), which was 35% greater than that of the group-average best intervention. A new randomized trial to confirm the external validity and applicability of the algorithm is warranted.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.